

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Department Regulation No. 1055, no persons are required to respond to a collection of information unless it displays a valid Office Control Number. Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/583,056
				Filing Date	March 16, 2007
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1644
				Examiner Name	G. R. Ewoldt
Sheet	1	of	4	Attorney Docket Number	ALEX-P01-112

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
	BH	WO-95/032734	12-07-1995	Innogenetics NV		
	BI	WO-00/63251	10-26-2000	Univ Nijmegen et al.		
	BJ	WO-02/50119	06-27-2002	Stichting Katholieke Universiteit		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO Those Application(s) which are marked with an single asterisk (*) next to the Cite No are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after year 2000, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). See Kinds Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two digit code (US and ST). Enter patent documents, the indication of the year of the Wipo of the document under the Wipo Standard ST. If possible, Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08b (03-09)
Approved for use through 04/30/2009 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/583,056
			Filing Date	March 16, 2007
			First Named Inventor	Katherine S. Bowdish
			Art Unit	1644
			Examiner Name	G. R. Ewoldt
			Attorney Docket Number	ALEX-P01-112
Sheet	2	of	4	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CC1	Purified Mouse Anti-Human Monoclonal Antibody, BD Pharmingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.		
	CD1	Amersdorfer et al., Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries. Infection and Immunity, 65, pp. 3743-3752 (1997)		
	CE1	Ahsan et al., Immunopathogenesis of Human Immunodeficiency Virus. Seminars in Nephrology, Vol. 18, No. 4, pages 422-435 (1998)		
	CF1	Berkower, I., et al., "CHIMERIC HIV-1 ENVELOPE GP120-HEPATITIS B CORE ANTIGEN (HbcAg) FUSION PROTEINS FOR HIV-1 VACCINES," FASEB Journal, 10(6):A1082 (1996).		
	CG1	Eck J., et al., "Cloning of the Mistletoe Lectin Gene and Characterization of the Recombinant A-Chain," European Journal of Biochemistry, 264:775-784 (1999).		
	CH1	FDA Approves Second Indication for Monoclonal Antibody, June 28, 1993, printed on November 12, 2004 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html , June 28, 1993.		
	CI1	Fè d'Ostiani, C., et al., "Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans: Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo," J. Exp. Med., 191(10):1661-1673 (2000).		
	CJ1	Forsyth, C. B., et al., "Interaction of the Fungal Pathogen Candida albicans with Integrin CD11b/CD18: Recognition by the I Domain is Modulated by the Lectin-Like Domain and the CD18 Subunit," The Journal of Immunology, 161:6198-6205 (1998).		
	CK1	Fumero et al., Immunosuppressive drugs as an adjuvant to HIV treatment. Journal of Antimicrobial Chemotherapy Vol. 53, pages 415-417 (2004)		
	CL1	Harlow and Lane, Antibodies, A Laboratory Manual. 1988 Cold Spring Harbor Laboratory, pages 141-142		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional) ²Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08b (03-09)

Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/583,056
		Filing Date	March 16, 2007
		First Named Inventor	Katherine S. Bowdish
		Art Unit	1644
		Examiner Name	G. R. Ewoldt
		Attorney Docket Number	ALEX-P01-112
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CM1	Katsoka et al., Cancer Research, 38(5), pp. 1202-1207 (1978) - Abstract only from Biosis database.	
	CN1	Marth, T., et al., "Regulation of Interleukin-12 by Complement Receptor 3 Signaling." The Journal of Experimental Medicine, 185(11):1987-1995 (1997).	
	CO1	Murdoch et al., Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Research and Therapy 4:9 (2007)	
	CP1	Netea, M. G., et al., "Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors," The Journal of Clinical Investigation, 116(6):1642-1650 (2006).	
	CQ1	Package insert for Orthoclone OKT3 Sterile Solution (murumonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised March 2001.	
	SR1	Product Information for Affinity Purified anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on January 5, 2004 from http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm	
	CS1	Rosati et al., Cytokine Response to Inactivated Candida albicans in Mice. Cell. Immunol., 162:256-264 (1995)	
	CT1	Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID NO: 2 from U.S.S.N. 09/719,961.	
	CU1	Stephen Smith. The pathogenesis of HIV infection: stupid may not be so dumb after all. Retrovirology 3:60 (2006)	
	CV1	Steinbrook, R., "One Step Forward, Two Steps Back - Will There Ever Be an AIDS Vaccine?," N. Engl. J. Med., 357:2653-2655 (2007).	

date?

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08b (03-09)

Approved for use through 04/30/2009 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/583,056
		Filing Date	March 16, 2007
		First Named Inventor	Katherine S. Bowdish
		Art Unit	1644
		Examiner Name	G. R. Ewoldt
		Attorney Docket Number	ALEX-P01-112
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CW1	Szabo, I., et al., "Modulation of Macrophage Phagocytic Activity by Cell Wall Components of <i>Candida albicans</i> ," <i>Cellular Immunology</i> , 164:182-188 (1995).	
	CX1	Taken, P.J., et al., "Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody," <i>Blood</i> , 106(4):1278-1285 (2005).	
	CY1	Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," <i>Circulation</i> , 97, pp. 2259-2267 (1998).	
	CZ1	Woodle, E.S., et al., Phase 1 Trial of Humanized, Fe Receptor Nonbinding OKT3 Antibody, huOKT3γ1(Ala-Ala) In the Treatment of Acute Renal Allograft Rejection. <i>Transplantation</i> , 68, pp. 608-616 (1999).	
	CA2	Yan et al., "b-Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 163(6):3045-3052 (1999).	

Examiner Signature	/Gerald Ewoldt/	Date Considered	09/27/2009
--------------------	-----------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached